1. Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study
- Author
-
Kurt S. Zänker, Ian O. Ellis, Melanie J Voss, Hany Onsy Habashy, Des G. Powe, Frank Entschladen, and Andrew R. Green
- Subjects
Adult ,Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Breast Neoplasms ,Kaplan-Meier Estimate ,Disease-Free Survival ,Metastasis ,Targeted therapy ,Breast cancer ,Receptors, Adrenergic, alpha-2 ,Receptors, Adrenergic, alpha-1 ,Internal medicine ,Biomarkers, Tumor ,Adrenergic antagonist ,medicine ,Humans ,Lymph node ,Tissue microarray ,business.industry ,Carcinoma, Ductal, Breast ,Middle Aged ,Prognosis ,medicine.disease ,Immunohistochemistry ,Tumor Burden ,Carcinoma, Lobular ,Endocrinology ,medicine.anatomical_structure ,Receptors, Estrogen ,Hormonal therapy ,Female ,Receptors, Adrenergic, beta-2 ,Neoplasm Grading ,business - Abstract
Breast cancer mortality is frequently associated with metastatic disease. Metastasis models have shown adrenoceptor (AR) stimulation induces cell migration which is inhibited by adrenoceptor antagonist drugs. We investigated adrenoceptor protein expression in clinical breast tumours and its association with disease progression and prognosis. Immunohistochemistry on tissue microarrays was used to characterise α1b, α2c and β22 adrenoceptor protein expression in operable breast tumours. Associations with tumour-relevant biological markers and clinical outcome were statistically assessed. Strong α1b expression occurred in large high grade (P
- Published
- 2011
- Full Text
- View/download PDF